Zylö’s ‘Powered By Z-pod’ Technology Featured in Peer-Reviewed Paper Published in Experimental Dermatology
27 sept. 2023 08h30 HE
|
Zylö Therapeutics
Z-pods significantly improved outcomes in mouse model of cutaneous lupus GREENVILLE, SC, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Z-pod® topical delivery platform was used in various in vivo...
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
06 sept. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...
How Indian outsourcing industry is moving up the value chain - Article published in TOI
28 déc. 2022 10h00 HE
|
Integra Global Solutions
Pittsburgh, PA, Dec. 28, 2022 (GLOBE NEWSWIRE) -- We are excited to announce that Ganesh Ranganathan, Chairman, and CEO of Integra Global Solutions’ article has been published in the Voices segment...
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
12 juil. 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their...
LiveCare Inc. Published PCAOB Audit For Fiscal Year 2021; Validates Proof of Concept
01 juin 2022 11h18 HE
|
LiveCare Inc.
Venice, FL USA, June 01, 2022 (GLOBE NEWSWIRE) -- LiveCare Inc. OTC:(LVCE), With the completion of its fiscal year 2021 PCAOB audit, validates its proof of concept as an innovative leader in the...
COLORESCIENCE® REVEALS CLINICAL STUDY RESULTS OF THE FINISHING TOUCH™ SKINCARE PROTOCOL FOLLOWING FACIAL RADIOFREQUENCY MICRONEEDLING PROCEDURES
25 mai 2022 08h45 HE
|
Colorescience
Carlsbad, CA, May 25, 2022 (GLOBE NEWSWIRE) -- In the midst of Skin Cancer Awareness Month, Colorescience®, a leading dermatologist-recommended specialty skincare and cosmetics company announces...
Hemispherx Biopharma Reports New Evidence -- Based Potential of Ampligen(R) Against Ebola Virus Disease (EVD)
30 oct. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today a new peer reviewed publication entitled, "The Quest for...
Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
04 août 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and...
Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction
08 avr. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and...